Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

• Published in: Frontiers in immunology Vol. 15; p. 1308109
• Main Authors: Lorenzi, Martina, Resi, Maria Vittoria, Bonanno, Laura, Frega, Stefano, Dal Maso, Alessandro, Ferro, Alessandra, Guarneri, Valentina, Pasello, Giulia
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2024
• Subjects: biomarkers; ES-SCLC; extensive stage small-cell lung cancer; immune checkpoint inhibitors (ICIs); Immunology; liquid biopsy; predictive role; extensive stage small-cell lung cancer; tumor immune microenvironment; biomarkers; ES-SCLC; immune checkpoint inhibitors (ICIs); predictive role; liquid biopsy
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1308109

Extensive stage-Small-Cell Lung Cancer (ES-SCLC) is an aggressive cancer with dismal prognosis. The addition of immune-checkpoint inhibitors (ICIs) to platinum-based chemotherapy have been consistently demonstrated to improve outcomes and survival, becoming the new standard in first - line treatment of ES-SCLC patients. However, despite positive results reported in the pivotal trials, longer benefit appears evident only for a selected group of patients. Several predictive biomarkers have been studied so far but the prospective identification of patients more likely to experience better outcome seems to be challenging in SCLC. Indeed, classical immune predictive biomarkers as PD-L1 and tumor mutational burden (TMB) seem not to correlate with outcomes. Recently, a new molecular classification of SCLC based on differential expression of genes associated with specific clinical behaviors and therapeutic vulnerability have been presented suggesting a new field to be investigated. Despite the achievements, these studies focused mainly on inter-tumoral heterogeneity, limiting the exploration of intra-tumoral heterogeneity and cell to cell interactions. New analysis methods are ongoing in order to explore subtypes plasticity. Analysis on single biopsies cannot catch the whole genomic profile and dynamic change of disease over time and during treatment. Moreover, the availability of tissue for translational research is limited due to the low proportion of patients undergoing surgery. In this context, liquid biopsy is a promising tool to detect reliable predictive biomarkers. Here, we reviewed the current available data on predictive role of tissue and liquid biomarkers in ES-SCLC patients receiving ICIs. We assessed latest results in terms of predictive and prognostic value of gene expression profiling in SCLC. Finally, we explored the role of liquid biopsy as a tool to monitor SCLC patients over time.